Used in targeted alpha therapy for cancer treatment, particularly in radiopharmaceutical applications. The compound serves as a bifunctional chelator system that links the alpha-emitting radionuclide Actinium-225 (225Ac) to targeting biomolecules such as monoclonal antibodies or peptides. Its structure allows stable conjugation to biomolecules via the maleimide propionate (MP) group, enabling site-specific binding to thiol groups on proteins. The galactose and glucosamine derivatives with benzylidene protection enhance solubility and in vivo stability, reducing premature release of the radionuclide. This construct is primarily investigated for treating disseminated cancers, such as metastatic prostate cancer and leukemia, where precise delivery of high-energy alpha radiation minimizes damage to surrounding healthy tissues.